Stay updated with breaking news from Jazz Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings,...
– 12% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –– Oncology revenues grew 13% year-over-year –– Submitted zanidatamab BLA for 2L...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) – Investment analysts at Zacks Research decreased their Q1 2024 earnings estimates for shares of Jazz Pharmaceuticals in a research note issued to investors on Wednesday, March 20th. Zacks Research analyst S. Ganoria now anticipates that the specialty pharmaceutical company will post earnings per share of $3.24 for […]
Full Year and Q4 2023 Earnings Overview: Key Financial and Operational Highlights